• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

NVIDIA, Harvard Team up on Genome Research Toolkit

Share:

March 17, 2021

NVIDIA is deepening its foothold in healthcare after teaming up with Harvard University on a new AI-based toolkit designed to help researchers gain more access and insights into DNA. Researchers also boast of being able to run a whole genome analysis in 30 minutes.

The new tool, dubbed AtacWorks, is able to identify specific sequencing data and pinpoint areas with easy-access DNA, meaning functional DNA that isn’t surrounded by proteins.

According to NVIDIA, “cells pull out only the subsection of genetic apparel that [they need] to function, with each cell type — such as liver, blood or skin cells — activating different genes.” Additionally, DNA regions that control a cell’s particular function are opened up for easier access.

AtacWorks works with ATAC-seq technology, which is a technique used to determine genome chromation accessibility.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“ATAC-seq is a widely-applied assay used to measure genome-wide chromatin accessibility. However, its ability to detect active regulatory regions can depend on the depth of sequencing coverage and the signal-to-noise ratio.

“Here we introduce AtacWorks, a deep-learning toolkit to de-noise sequencing coverage and identify regulatory peaks at base-pair resolution from low cell count, low-coverage or low-quality ATAC-seq data,” researchers wrote in a study published on the technology in Nature.

“Models trained by AtacWorks can detect peaks from cell types not seen in the training data, and [that] are generalizable across diverse sample preparations and experimental platforms.”

WHAT IT’S FOR

NVIDIA has often discussed the future of genomics. This development signals the company’s intentions to develop tools in the space.

“There are some great things brewing in genomics,” Kimberly Powell, the vice president of healthcare at NVIDIA, told MobiHealthNews in 2019.

“Deep learning in genomics research is on the same sort of acceleration curve for deep learning overall, which means what happens in research is going to start translating into the rest of the world. I think AI and genomics [are] going to be a concentration moving forward, and a real opportunity.”

THE LARGER TREND

Over the last year NVIDIA has rolled out a number of health-related initiatives. In September, the company rolled out its automated speech recognition and natural language processing technology that can transcribe and organize information from a telemedicine visit for patients and clinicians.

More recently the tech giant announced it would build a supercomputer for U.K. healthcare researchers.

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Privacy-minded Consumers More Likely to Share Health Data If Transparency and Altruistic Use are GuaranteedPrivacy-minded Consumers More Likely to Share Health Data If Transparency and Altruistic Use are Guaranteed
  • Ochsner Health System and Pfizer team up to rethink clinical trialsOchsner Health System and Pfizer team up to rethink clinical trials
  • Spectrum Pharma Is Weighing a SaleSpectrum Pharma Is Weighing a Sale
  • Evotec SE to Acquire Just Biotherapeutics, Inc.Evotec SE to Acquire Just Biotherapeutics, Inc.
  • Global COVID-19 Treatment Industry Top-Vendor And Industry Insights By End-User Segments Till 2027Global COVID-19 Treatment Industry Top-Vendor And Industry Insights By End-User Segments Till 2027
  • Bluma Wellness Announces Shareholder Approval for Proposed Plan of Arrangement with Cresco LabsBluma Wellness Announces Shareholder Approval for Proposed Plan of Arrangement with Cresco Labs
  • 5 Healthcare M&A Trends in 2019 — Ambulatory Surgery Deals, PE Integrations & More5 Healthcare M&A Trends in 2019 — Ambulatory Surgery Deals, PE Integrations & More
  • Synergy Laboratories Acquires Pathology Laboratory Associates to Broaden Its Medical Testing ExpertiseSynergy Laboratories Acquires Pathology Laboratory Associates to Broaden Its Medical Testing Expertise

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications